| dc.contributor.author | Arik N. | |
| dc.contributor.author | Adam B. | |
| dc.contributor.author | Akpolat T. | |
| dc.contributor.author | Haşil K. | |
| dc.contributor.author | Tabak S. | |
| dc.date.accessioned | 2020-06-21T09:19:41Z | |
| dc.date.available | 2020-06-21T09:19:41Z | |
| dc.date.issued | 1996 | |
| dc.identifier.issn | 0301-1623 | |
| dc.identifier.uri | https://doi.org/10.1007/BF02550974 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/3116 | |
| dc.description | PubMed: 9119652 | en_US |
| dc.description.abstract | In order to assess the clinical value of six tumour markers in pre-dialysis patients with chronic renal failure as well as in patients on regular haemodialysis, we studied these markers in 35 predialysis patients, 35 patients on chronic haemodialysis and 35 healthy controls. Serum squamous cell antigen (SCC), CA 19.9, and CA 125 levels were found to be elevated in the uraemic groups as compared to the normal controls. Carcinoembryonic antigen (CEA), alpha foetoprotein (AFP), and prostate-specific antigen (PSA) levels were within normal limits in all groups. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Kluwer Academic Publishers | en_US |
| dc.relation.isversionof | 10.1007/BF02550974 | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Serum tumour markers in renal failure | en_US |
| dc.type | article | en_US |
| dc.contributor.department | OMÜ | en_US |
| dc.identifier.volume | 28 | en_US |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.startpage | 601 | en_US |
| dc.identifier.endpage | 604 | en_US |
| dc.relation.journal | International Urology and Nephrology | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
